It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Proteomic studies of human Alzheimer’s disease brain tissue have potential to identify protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 published Alzheimer’s disease proteomic studies, generating a map of protein changes in human brain tissue across thirteen brain regions, three disease stages (preclinical Alzheimer’s disease, mild cognitive impairment, advanced Alzheimer’s disease), and proteins enriched in amyloid plaques, neurofibrillary tangles, and cerebral amyloid angiopathy. Our dataset is compiled into a searchable database (NeuroPro). We found 848 proteins were consistently altered in 5 or more studies. Comparison of protein changes in early-stage and advanced Alzheimer’s disease revealed proteins associated with synapse, vesicle, and lysosomal pathways show change early in disease, but widespread changes in mitochondrial associated protein expression change are only seen in advanced Alzheimer’s disease. Protein changes were similar for brain regions considered vulnerable and regions considered resistant. This resource provides insight into Alzheimer’s disease brain protein changes and highlights proteins of interest for further study.
Proteomic studies in Alzheimer’s disease may be useful for understanding disease mechanisms and potential therapeutic targets. Here the authors describe a resource collating known protein changes throughout the progression of Alzheimer’s disease in human brain tissue.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Biomedical Hosting LLC, Arlington, USA
2 University of Sydney, Brain and Mind Centre and School of Medical Sciences, Camperdown, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X)
3 New York University, Center for Cognitive Neurology, Department of Neurology, Grossman School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)
4 New York University, Center for Cognitive Neurology, Department of Neurology, Grossman School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753); New York University, Proteomics Laboratory, Division of Advanced Research Technologies, Grossman School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753); New York University, Biochemistry and Molecular Pharmacology, Grossman School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)
5 University of Sydney, Brain and Mind Centre and School of Medical Sciences, Camperdown, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); New York University, Center for Cognitive Neurology, Department of Neurology, Grossman School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)